Theriva Biologics shares are trading higher after the company announced the FDA granted orphan drug designation to orphan drug designation for pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has announced that the FDA has granted orphan drug designation for its pancreatic cancer drug. This news has led to a rise in the company's share prices.
June 27, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics' shares are trading higher after the FDA granted orphan drug designation for its pancreatic cancer drug.
The FDA's orphan drug designation is a significant milestone for Theriva Biologics as it provides the company with certain benefits, including market exclusivity upon regulatory approval, tax credits for qualified clinical trials and waiver of certain administrative fees. This positive news is likely to boost investor confidence, leading to a rise in the company's share prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100